【摘要】：目的:對國內(nèi)外降血脂藥物專利信息進行情報挖掘,旨在為相關(guān)領(lǐng)域的醫(yī)藥研發(fā)人員揭示該領(lǐng)域藥物的研發(fā)現(xiàn)狀,分析專利技術(shù)的發(fā)展階段,熱點技術(shù)領(lǐng)域及核心技術(shù),核心專利申請機構(gòu)等相關(guān)信息,也有助于相關(guān)制藥企業(yè)確定研究重心及制定發(fā)展戰(zhàn)略。方法:采用社會網(wǎng)絡(luò)分析法、聚類分析法等方法,對國家知識產(chǎn)權(quán)局專利檢索系統(tǒng)及德溫特專利數(shù)據(jù)庫中的降血脂藥物專利信息進行分析,分析角度包括:歷年專利申請量分析、專利技術(shù)生命周期分析、專利申請人數(shù)量及合作網(wǎng)絡(luò)分析、專利技術(shù)引文分析及專利技術(shù)聚類分析。結(jié)果:國內(nèi)降血脂藥物專利申請量以及申請人數(shù)量呈上升趨勢;專利申請量受地區(qū)經(jīng)濟及政策狀況的影響明顯;科研院校的研發(fā)重心集中在化學(xué)合成類藥物專利,企業(yè)重心多集中在天然植物提取物類專利;當(dāng)前的核心技術(shù)集中在他汀類藥物及天然植物提取物的研發(fā)當(dāng)中。國際降血脂藥物專利申請量呈增長趨勢;技術(shù)也已進入成熟期,核心機構(gòu)分別是默克集團、瑞士羅氏制藥以及勃林格殷格翰集團,核心企業(yè)間的合作較少;熱點技術(shù)領(lǐng)域集中在傳統(tǒng)中藥及其制劑、治療脂質(zhì)紊亂類藥物以及新型胍基衍生物三大領(lǐng)域當(dāng)中;同時各核心機構(gòu)在熱點技術(shù)領(lǐng)域均有較多專利。結(jié)論:國內(nèi)外降血脂藥物專利技術(shù)的研發(fā)熱點均集中在傳統(tǒng)中藥及其制劑、治療脂質(zhì)紊亂類藥物以及新型胍基衍生物三大領(lǐng)域當(dāng)中。目前我國的研發(fā)水平不斷提高,研發(fā)隊伍不斷壯大,其中化學(xué)合成類藥物的主要研發(fā)力量為各大科研院校。同時從總體地域分布來看地區(qū)政策對企業(yè)的發(fā)展有著重要影響。目前國際上的幾大核心醫(yī)藥企業(yè)合作較少,但科研能力及創(chuàng)新水平較高,其目前關(guān)注的重點是PCSK9抑制劑藥物的研發(fā),在整體技術(shù)都已進入成熟期階段的情況下,大力開發(fā)新技術(shù),能夠幫助企業(yè)更好的搶占市場先機。
[Abstract]:Objective: to explore the patent information of hypolipidemic drugs at home and abroad in order to reveal the current situation of drug research and development in related fields and analyze the development stage of patent technology, hot technology field and core technology. Relevant information, such as core patent application agencies, can also help pharmaceutical companies determine their research focus and formulate development strategies. Methods: the patent information of hypolipidemic drugs in the patent retrieval system of the State intellectual property Office and the Derwent patent database were analyzed by the methods of social network analysis and cluster analysis. The analysis includes: patent application volume analysis, patent technology life cycle analysis, patent applicant number and cooperation network analysis, patent technology citation analysis and patent technology cluster analysis. Results: the number of patent applications and the number of applicants for hypolipidemic drugs were on the rise in China, and the amount of patent applications was obviously affected by the regional economy and policy. The research and development of scientific research colleges focus on the patent of chemical synthetic medicine, and the focus of enterprises is on the patent of natural plant extract; the current core technology is focused on the research and development of statins and natural plant extracts. The number of international patent applications for hypolipidemic drugs is on the rise, and the technology has entered a mature stage. The core institutions are Merck Group, Swiss Roche Pharmaceutical Group and Brig Ingham Group, with less cooperation among the core enterprises. The hot technology field is concentrated in the traditional Chinese medicine and its preparation, the treatment of lipid disorder drugs and the new guanidinyl derivatives. At the same time, the core institutions have more patents in the hot technology field. Conclusion: the research and development of antilipidemic drugs at home and abroad are focused on traditional Chinese medicine and its preparations, lipids and new guanidinyl derivatives. At present, the R & D level of our country is improving and the R & D team is growing. The main R & D force of chemosynthetic drugs is the major research institutes. At the same time, from the overall geographical distribution, regional policies have an important impact on the development of enterprises. At present, there is little cooperation among the major core pharmaceutical enterprises in the world, but the scientific research capability and innovation level are relatively high. At present, their focus is on the research and development of PCSK9 inhibitor drugs, while the overall technology has entered the mature stage. Vigorously develop new technologies, can help enterprises better seize market opportunities.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R972.6;F426.72

【參考文獻】

相關(guān)期刊論文 前10條

1 曲超;王永強;朱虹;劉蘭茹;;醫(yī)藥企業(yè)專利傾向研究[J];中國醫(yī)藥工業(yè)雜志;2016年04期

2 陳偉偉;高潤霖;劉力生;朱曼璐;王文;王擁軍;吳兆蘇;李惠君;鄭哲;蔣立新;胡盛壽;;《中國心血管病報告2014》概要[J];中國循環(huán)雜志;2015年07期

3 隋輝;陳偉偉;王文;;《中國心血管病報告2014》要點介紹[J];中華高血壓雜志;2015年07期

4 楊靜;;降血脂藥物的研究進展[J];臨床醫(yī)藥文獻電子雜志;2015年14期

5 劉思齊;楊悅;;立普妥的專利保護策略研究[J];中國新藥雜志;2014年09期

6 郭東杰;袁肖寒;蔡曼;顧成波;祖元剛;;降血脂西藥與中藥研究現(xiàn)狀與展望[J];黑龍江醫(yī)藥;2014年01期

7 滕廣青;牟冬梅;任晶;;國外社會網(wǎng)絡(luò)分析在文獻計量領(lǐng)域的應(yīng)用研究[J];情報資料工作;2014年01期

8 金福蘭;李向輝;趙斐;湯m，

本文編號：2305525